Bausch Company Profile

What is the competitive landscape for BAUSCH

BAUSCH has one hundred and seventy-eight approved drugs.

There are one hundred and sixteen US patents protecting BAUSCH drugs.

There are seven hundred and eighty-two patent family members on BAUSCH drugs in fifty-three countries and two hundred and fourteen supplementary protection certificates in sixteen countries.

Summary for Bausch

International Patents:	782
US Patents:	116
Tradenames:	156
Ingredients:	122
NDAs:	178
Patent Litigation for Bausch:	See patent lawsuits for Bausch

Drugs and US Patents for Bausch

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	ISORDIL	isosorbide dinitrate	TABLET;ORAL	012093-007	Jul 29, 1988	AB	RX	Yes	No
Bausch	JUBLIA	efinaconazole	SOLUTION;TOPICAL	203567-001	Jun 6, 2014	AB	RX	Yes	Yes	9,566,272
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-005	Jul 23, 2009		DISCN	Yes	No	8,268,804

Expired US Patents for Bausch

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch	CARDIZEM	diltiazem hydrochloride	TABLET;ORAL	018602-004	Dec 8, 1986	3,706,789
Bausch	ELIDEL	pimecrolimus	CREAM;TOPICAL	021302-001	Dec 13, 2001	5,912,238*PED
Bausch And Lomb	VYZULTA	latanoprostene bunod	SOLUTION/DROPS;OPHTHALMIC	207795-001	Nov 2, 2017	7,910,767

Paragraph IV (Patent) Challenges for BAUSCH drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Ophthalmic Solution	1.5%		2013-09-09
	Gel	1.2%/0.025%		2010-12-17
	Gel	0.77%		2006-05-10
	Lotion	0.1%		2016-08-31
	Extended-release Tablets	174 mg		2009-09-28
	Cream	3.75%		2012-08-08
	Extended-release Tablets	522 mg		2009-12-24
	For Inhalation Solution	6 gm/vial		2014-05-22
	Extended-release Tablets	420 mg		2005-04-25
	Rectal Gel	5 mg/mL, 4mL pre-filled syringe		2008-12-08
	Extended-release Tablet	55 mg and 80 mg		2010-12-02
	Gel	1.2%/2.5%		2012-12-20
	Extended-release Tablets	150 mg and 300 mg		2004-09-21
	Gel	0.1%		2010-07-08
	Ophthalmic Solution	0.07%		2013-07-26
	Capsules	75 mg		2011-06-06
	Vaginal Gel	0.75%		2004-09-02
	Cream	5%		2006-10-17
	Topical Solution	10%		2018-06-06
	Cream	0.10%		2008-01-31
	Extended-release Tablets	348 mg		2009-09-24
	Cream	2.5%		2014-06-17
	Extended-release Tablets	120 mg, 180 mg, 240 mg, 300 mg and 360 mg		2005-08-30
	Rectal Gel	2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL, 15 mg/3 mL and 20 mg/4 mL		2004-03-23
	Extended-release Tablets	65 mg and 115 mg		2009-11-19
	Rectal Gel	5 mg/mL, 2mL pre-filled syringe		2008-12-23
	Extended-release Tablet	105 rng		2010-12-28
	Gel	1.2%/3.75%		2015-09-30
	Ophthalmic Solution	0.5%		2012-10-19
	Gel	0.04%		2010-12-20

International Patents for Bausch Drugs

Country	Patent Number	Estimated Expiration
China	100469765
Lithuania	3310389
Singapore	183695

Supplementary Protection Certificates for Bausch Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1499331	13C0055	France		PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: BE - 434323 20130220
2316456	17C1058	France		PRODUCT NAME: NALTREXONE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER CHLORHYDRATE DE NALTREXONE ET,BUPROPION OU SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER CHLORHYDRATE DE BUPROPION; REGISTRATION NO/DATE: EU/1/14/988 20150330
0427680	SZ 12/2003	Austria		PRODUCT NAME: PIMECROLIMUS, GEGEBENENFALLS IN FORM PHARMAZEUTISCH ANNEHMBARER SALZE

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Bausch
• Bausch And Lomb
• Bausch And Lomb Inc

Pharmaceutical Competitive Landscape Analysis: Bausch Health's Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, Bausch Health has emerged as a significant player, carving out a unique position for itself. This comprehensive analysis delves into Bausch Health's market standing, competitive advantages, and strategic direction, offering valuable insights for industry professionals and investors alike.

Bausch Health's Market Position

Bausch Health has established a strong foothold in the pharmaceutical market, particularly in the fields of neurology, dermatology, and infectious diseases. As of February 2025, the company reported a market capitalization of CAD 3.79 billion, reflecting its substantial presence in the industry[1].

Market Share and Competitive Standing

According to recent data from Q3 2024, Bausch Health held a market share of 1.73% in its sector, showcasing its competitive position among industry giants[4]. While this may seem modest, it's important to note that the pharmaceutical market is highly fragmented, with numerous players vying for market share.

"Bausch Health's market position is built on a foundation of innovation, quality, and patient-centric care. By staying at the forefront of medical research and maintaining a strong focus on meeting the needs of patients, Bausch Health has established itself as a leader in the pharmaceutical industry."[3]

Key Strengths of Bausch Health

Diverse Product Portfolio

One of Bausch Health's primary strengths lies in its diverse product portfolio. The company offers a wide range of medications across various therapeutic areas, allowing it to cater to multiple market segments and reduce dependency on any single product line[3].

Strong R&D Capabilities

Bausch Health's commitment to research and development is evident in its substantial R&D investments. In 2021, the company allocated approximately $465 million to R&D, representing about 6% of its revenue[2]. This focus on innovation helps Bausch Health maintain its competitive edge and continually bring new products to market.

Global Presence

With operations spanning multiple countries, Bausch Health benefits from a strong global presence. This international footprint allows the company to tap into diverse markets and mitigate risks associated with regional economic fluctuations[3].

Strategic Initiatives and Future Outlook

Focus on Core Therapeutic Areas

Bausch Health has strategically aligned its business to focus on core therapeutic areas with attractive growth opportunities. This approach has simplified operations and increased the value of key business segments, including eye health, gastrointestinal, and dermatology[2].

Expansion into Emerging Markets

The company is actively exploring opportunities to expand its presence in emerging markets. This strategy aims to capitalize on the growing demand for healthcare products in these regions and diversify revenue streams[3].

Digital Health Initiatives

Recognizing the increasing importance of digital health technologies, Bausch Health is investing in telemedicine, remote patient monitoring, and digital therapeutics. These initiatives are expected to enhance patient care and improve treatment outcomes[3].

Competitive Challenges and Industry Trends

Intense Market Competition

Bausch Health operates in a highly competitive market, facing stiff competition from both established pharmaceutical giants and emerging players. As of 2024, the company had approximately 127 direct competitors in the pharmaceutical and generic drug sectors[9].

Patent Expirations

Like many pharmaceutical companies, Bausch Health faces challenges related to patent expirations. Key products such as Xifaxan and Wellbutrin XL are approaching patent expiration, potentially impacting future revenues[9].

Regulatory Environment

The pharmaceutical industry is subject to stringent regulations, and compliance costs are on the rise. Bausch Health's regulatory compliance expenses increased by 22% in 2023, with projected costs reaching $124 million in 2024[9].

Financial Performance and Outlook

Recent Financial Results

In the fourth quarter of 2023, Bausch Health reported total revenue of $1.173 billion, representing an 18% increase compared to the same period in 2022. For the full year 2023, revenue reached $4.146 billion, growing 10% year-over-year[10].

Segment Performance

Bausch Health's revenue growth in 2023 was driven by strong performance across all segments:

• Vision Care: 6% growth in Q4 2023
• Surgical: 9% growth in Q4 2023
• Pharmaceuticals: 67% growth in Q4 2023[10]

2024 Guidance

While specific guidance for 2024 was not provided in the available information, the company's strong performance in 2023 sets a positive tone for the future. CEO Brent Saunders stated, "Revenue growth in 2023, and in the fourth quarter in particular, exceeded our expectations and set the tone for 2024."[10]

Strategic Partnerships and Collaborations

Bausch Health recognizes the value of strategic partnerships in driving innovation and growth. The company has formed alliances with other pharmaceutical firms, research institutions, and healthcare organizations to enhance its product portfolio and expand market reach[3].

Sustainability and Corporate Social Responsibility

In line with growing consumer expectations, Bausch Health is placing increased emphasis on sustainability and corporate social responsibility. The company is implementing sustainable practices and supporting community initiatives to enhance its brand reputation and contribute positively to society[3].

Key Takeaways

• Bausch Health holds a significant position in the pharmaceutical market, with a diverse product portfolio and strong R&D capabilities.
• The company's focus on core therapeutic areas and expansion into emerging markets positions it for future growth.
• Challenges include intense competition, patent expirations, and increasing regulatory compliance costs.
• Strong financial performance in 2023 sets a positive tone for 2024 and beyond.
• Strategic partnerships and a focus on sustainability are key elements of Bausch Health's long-term strategy.

FAQs

1. What are Bausch Health's main therapeutic areas? Bausch Health focuses primarily on neurology, dermatology, and infectious diseases.

2. How much does Bausch Health invest in R&D? In 2021, Bausch Health invested approximately $465 million in R&D, representing about 6% of its revenue.

3. What is Bausch Health's market share? As of Q3 2024, Bausch Health held a market share of 1.73% in its sector.

4. How has Bausch Health's revenue grown recently? In Q4 2023, Bausch Health's revenue grew 18% year-over-year, while full-year 2023 revenue increased by 10%.

5. What are the main challenges facing Bausch Health? Key challenges include intense market competition, patent expirations for key products, and increasing regulatory compliance costs.

Sources cited: [1] https://tradingeconomics.com/vrx:cn:market-capitalization [2] https://market.us/statistics/pharmaceutical-industry/bausch-health/ [3] https://canvasbusinessmodel.com/blogs/competitors/bausch-health-competitive-landscape [4] https://csimarket.com/stocks/competitionSEG2.php?code=BHC [9] https://dcfmodeling.com/products/bhc-swot-analysis [10] https://ir.bausch.com/press-releases/bausch-lomb-announces-fourth-quarter-and-full-year-2023-results-and-provides-2024